Copyright 2008 Medical News Today Latest Immune System / Vaccines News From Medical News Today. http://www.medicalnewstoday.com/sections/immune_system/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Tue, 08 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/114172.php Six of every 100 patients who die in hospital do so as a consequence of an adverse drug reaction or, in other words, a fatal reaction to medicines. Those are the conclusions of a research carried out at the Department of Medicine of the University of Granada, in collaboration with the Clinical Hospital San Cecilio of Granada, by Alfredo Jose Pardo Cabello and directed by Professors Emilio Puche Canas (Department of Pharmacology) and Francisco Javier Gomez Jimenez (Department of Medicine). Tue, 08 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114145.php Vaccinating infants and toddlers is an almost universal practice in the United States. Vaccines to prevent flu are a regular part of medical care for senior citizens and at-risk patients. But, according to a study published in the August 2008 issue of the American Journal of Preventive Medicine, the US healthcare system is not very effective in getting vaccines to the adolescent population. Mon, 07 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/114091.php Our bodies rely on the production of potent, or 'high affinity', antibodies to fight infection. The process is very complex, yet Sydney scientists have discovered that it hinges on a single molecule, a growth factor, without which it cannot function. There is much we do not yet understand about our immune system. In simple terms, our bodies produce B cells, which make antibodies, and T cells, which help them. Mon, 07 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/114075.php Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that a research team led by a Resolvyx scientific advisor and a company co-founder has demonstrated that the resolvin E1 (RvE1) effectively suppresses IL-23 and IL-17, two key inflammatory mediators of chronic inflammatory disease, in a preclinical model of asthma. RvE1 is the active ingredient in RX-10001, one of Resolvyx's leading clinical candidates. Sun, 06 Jul 2008 11:00:00 PDT http://www.medicalnewstoday.com/articles/114055.php Diabetes mellitus is a metabolic disorder characterized by altered glucose tolerance and impaired lipid and carbohydrate metabolism, and is associated with a number of complications directly resulting from hyperglycemiainduced inflammation. Vascular changes in diabetes lead to increased risk of myocardial infarction and stroke due to atherosclerosis, retinopathy, end-stage renal disease, debilitating neuropathies, poor wound healing, enhanced risk of infection, and periodontal disease. Sun, 06 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114036.php Free Vaccine Inc., a non-profit organization dedicated to raising awareness about vaccine-preventable diseases and empowering individuals to be a part of the solution, has launched GiveVaccines.org. The site features a fast-paced vocabulary quiz focusing on word roots, English words and medical terminology. For every correct answer, GiveVaccines. Sun, 06 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114035.php Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms, is pleased to announce a research publication on its DispersinBTM technology. The manuscript appeared in the recent online edition of Microbial Pathogenesis (2008), doi: 10/1016/j.micpath.2008.05.007. Sun, 06 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114033.php Medicago Inc. (TSX VENTURE:MDG) announced it has been awarded a non-refundable contribution of up to $279,700 from Canada's National Research Council Industrial Research Assistance Program ("NRC-IRAP") to support the development of the Company's seasonal influenza Virus-Like Particles (VLP) vaccine program. Medicago is developing a seasonal vaccine based on its proprietary VLP manufacturing technology, which has the potential to offer speed and cost advantages over competitive technologies. Fri, 04 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/113964.php Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported additional interim results from its ongoing phase I/II clinical study of its ChronVac-C® therapeutic DNA vaccine, which is delivered using Inovio's electroporation-based DNA delivery system. Thu, 03 Jul 2008 05:00:00 PDT http://www.medicalnewstoday.com/articles/113850.php Thanks to salt and hot chili peppers, researchers have found a calculus-computing center that tells a roundworm to go forward toward dinner or turn to broaden the search. It's a computational mechanism, they say, that is similar to what drives hungry college students to a pizza. Thu, 03 Jul 2008 05:00:00 PDT http://www.medicalnewstoday.com/articles/113837.php VGX Pharmaceuticals, Inc. (VGX) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its DNA vaccine for cervical cancer therapy, VGX-3100. The Company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. More information on this study is available Thu, 03 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113703.php Service personnel deployed to Iraq have not suffered ill health due to multiple vaccinations, according to a study released on July 1, 2008 in BMJ. Debate related to the impact that multiple vaccinations may have had on the health of veterans of the Gulf War will only be fueled by this new information. Before deployment to Iraq in 2003 and later, vaccines against tetanus, typhoid, and yellow fever are routinely administered to service personnel. Wed, 02 Jul 2008 07:00:00 PDT http://www.medicalnewstoday.com/articles/113682.php A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a report in the October Journal of the American Society of Nephrology (JASN). "In our study, multi-target therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects," comments Dr. Wed, 02 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/113522.php Scientists have found that vaccination with a heat-killed, nontoxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice. Vaccination extends overall survival and reduces tumor size in mice that have been injected with cancer cells displaying the same protein that was engineered into the yeast. Tue, 01 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/113401.php Recent scientific findings explain why patients with a rare immunodeficiency disorder are unusually susceptible to certain common infections. By revealing the exact molecular mechanisms involved, they also give us clues as to why some 'healthy' people are more prone to these infections than others, and suggest potential treatments. Mon, 30 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/113273.php Diagnostic HYBRIDS has received funding through the Biomedical Research Commercialization Program (BRCP) to develop more sensitive and affordable assays for the monitoring of patients infected with Human Immunodeficiency Virus (HIV) and/or Hepatitis C Virus (HCV) and to produce vaccines against influenza virus. The BRCP is part of the Third Frontier Project, a push by Ohio lawmakers to bring biotechnology and related businesses into the state of Ohio. Mon, 30 Jun 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113252.php Researchers at the Uniformed Services University of the Health Sciences (USU) have been awarded a $5.6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop and test vaccines and treatments for the deadly Nipah and Hendra viruses. Christopher C. Broder, Ph.D. Fri, 27 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/112969.php Health care professionals should increase influenza immunization rates by implementing key, practice-proven interventions and offering vaccine at every opportunity throughout the entire influenza season, conclude leading influenza experts in a July 2008 supplement to The American Journal of Medicine. Fri, 27 Jun 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/112896.php To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS (DAIDS). Thu, 26 Jun 2008 07:00:00 PDT http://www.medicalnewstoday.com/articles/112908.php GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved KINRIX™ [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine], the first combination vaccine to offer protection against diphtheria, tetanus, pertussis and polio diseases in one shot. Thu, 26 Jun 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/112897.php To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS (DAIDS). Thu, 26 Jun 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/112886.php A unique technique for analyzing the function of microRNAs developed by a Hebrew University of Jerusalem doctoral student has led to the discovery of a new mechanism by which viruses evade the human immune system. This discovery has important implications for human intervention in the battle between viruses and humans. For her work in this field, Naama Elefant, a student of Prof. Thu, 26 Jun 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/112876.php Oregano doesn´t only give a Pizza its typical taste. Researchers at Bonn University and the ETH Zurich have discovered that this spice also contains a substance which, amongst other qualities, appears to help cure inflammations. The researchers administered its active ingredient - known as beta-caryophyllin (E-BCP) - to mice with inflamed paws. In seven out of ten cases there was a subsequent improvement in the symptoms. Thu, 26 Jun 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/112749.php Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide. This new 100 million euros facility located in Val de Reuil (North West of France) incorporates the latest technology to produce vaccines that meet the highest standards of quality. Wed, 25 Jun 2008 11:00:00 PDT http://www.medicalnewstoday.com/articles/112750.php The US Food and Drug Administration (FDA) announced yesterday that it had given approval for the first new combination vaccine for protecting 4 to 6 year old children against diphtheria, tetanus, pertussis and polio diseases in one shot, made by GlaxoSmithKline (GSK). The vaccine is branded as the trademarked name KINRIX, and its official long name is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine.